Citigroup Cuts Cencora (NYSE:COR) Price Target to $355.00

Key Points

• Citigroup cut its price target on Cencora from $405 to $355 but kept a "buy" rating, a level that still implies roughly a 39% upside from the stock's prior close.
• Cencora missed Q2 estimates (EPS $4.75 vs. $4.82; revenue $78.36B vs. ~$81B) but raised FY‑2026 adjusted EPS guidance to $17.65–$17.90 and authorized a $1 billion share buyback, producing a mixed near‑term outlook.
• The market reacted sharply to revenue headwinds and the guidance trim, with shares trading near $254.90 and hitting 52‑week lows, even as analysts' average price target remains about $391.58 and institutional ownership is ~97.5%.

Cencora (NYSE:COR - Get Free Report) had its price objective reduced by analysts at Citigroup from $405.00 to $355.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a "buy" rating on the stock. Citigroup's target price would suggest a potential upside of 39.27% from the stock's previous close.

Several other equities analysts have also recently issued reports on the company. William Blair started coverage on Cencora in a research note on Tuesday, April 28th. They set a "market perform" rating on the stock. Barclays raised their target price on shares of Cencora from $400.00 to $425.00 and gave the stock an "overweight" rating in a research report on Friday, February 13th. Weiss Ratings reiterated a "buy (b)" rating on shares of Cencora in a research report on Monday. JPMorgan Chase & Co. increased their price target on shares of Cencora from $417.00 to $419.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 10th. Finally, Leerink Partners restated an "outperform" rating on shares of Cencora in a report on Tuesday, March 17th. Twelve equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $391.58.

Cencora Trading Up 0.9%

Shares of NYSE:COR traded up $2.16 during midday trading on Thursday, hitting $254.90. 3,699,493 shares of the stock traded hands, compared to its average volume of 1,444,454. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62. The business's 50 day moving average is $330.01 and its two-hundred day moving average is $342.75. The stock has a market capitalization of $49.58 billion, a PE ratio of 30.64, a P/E/G ratio of 1.43 and a beta of 0.64. Cencora has a one year low of $244.82 and a one year high of $377.54.

Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a return on equity of 176.54% and a net margin of 0.50%.The business had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. During the same period in the previous year, the business earned $4.42 earnings per share. The firm's revenue for the quarter was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, research analysts forecast that Cencora will post 17.58 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of COR. Kemnay Advisory Services Inc. bought a new position in Cencora in the 4th quarter valued at approximately $25,000. Oakworth Capital Inc. purchased a new stake in Cencora during the 4th quarter valued at $26,000. Elyxium Wealth LLC bought a new stake in shares of Cencora in the 4th quarter worth $27,000. Archer Investment Corp raised its stake in shares of Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company's stock worth $28,000 after purchasing an additional 47 shares during the last quarter. Finally, Motiv8 Investments LLC purchased a new position in shares of Cencora in the fourth quarter worth $29,000. 97.52% of the stock is currently owned by institutional investors.

More Cencora News

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Management raised fiscal‑2026 adjusted EPS guidance to $17.65–$17.90 and authorized a $1 billion share‑repurchase program — gives investors clearer upside to earnings and supports the stock. Cencora signals FY2026 EPS of 17.65-17.90 while resuming $1B share repurchases
• Positive Sentiment: OneOncology integration and higher‑margin businesses helped expand gross margins and drove the quarter’s profit beat on a non‑GAAP basis, underpinning the raised EPS outlook. Cencora lifts 2026 outlook after OneOncology-fueled earnings jump
• Positive Sentiment: The board declared a quarterly dividend of $0.60 per share, adding a modest income component for holders (ex‑dividend May 15).
• Neutral Sentiment: Robert W. Baird cut its price target from $420 to $339 but kept an "Outperform" rating — a mixed signal that trims near‑term upside assumptions while leaving a constructive view intact. Price target cut by Robert W. Baird
• Negative Sentiment: Q2 results missed Street expectations: adjusted EPS $4.75 (vs. ~$4.82 est.) and revenue $78.4B (below consensus ~ $81B), prompting investor concern about near‑term performance. Cencora raises annual profit forecast despite quarterly miss
• Negative Sentiment: Management trimmed revenue growth expectations and called out U.S. Healthcare Solutions headwinds — branded‑drug price cuts, reduced volumes to a large mail‑order client and prior customer losses — which pressured the stock. Cencora Shares Drop on Revenue Outlook Cut
• Negative Sentiment: The market reacted sharply after the report (shares plunged and hit 52‑week lows), reflecting investor worry that near‑term demand/mix issues outweigh the improved EPS guidance. Cencora hits 52-week low after guidance cut

Cencora Company Profile

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.